From: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
 | No CRS | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
---|---|---|---|---|---|
Number of patients, n (%) | 24 (57.1) | 2 (4.8) | 7 (16.7) | 4 (9.5) | 5 (11.9) |
Among patients with CRS* | |||||
CRS grade-defining events | |||||
 Hypotension that required intervention, n (%) | – | 0 | 0 | 2 (50.0) | 5 (100) |
  High-dose vasopressors used, n (%) | – | – | – | 0 | 3 (60.0) |
 Oxygen supplementation given, n (%) | – | 0 | 0 | 2 (50.0) | 5 (100) |
 Patient intubated, n (%) | – | 0 | 0 | 0 | 2 (40.0) |
  Duration (days) | |||||
   Mean (SD) | – | – | – | – | 21.0 (16.97) |
   Median (range) | – | – | – | – | 21.0 (9.0–33.0) |
 Disseminated intravascular coagulation observed, n (%) | – | 0 | 0 | 0 | 0 |
  Bleeding observed, n (%) | – | – | – | – | – |
  Blood product support given for bleeding, n (%) | – | – | – | – | – |
CRS timing | |||||
 Time to onset of CRS (days) | |||||
  Mean (SD) | – | 8.0 (8.49) | 7.3 (4.39) | 22.5 (32.59) | 2.4 (3.13) |
  Median (range) | – | 8.0 (2.0–14.0) | 9.0 (1.0–13.0) | 9.0 (1.0–71.0) | 1.0 (1.0–8.0) |
 Duration of CRS (days) | |||||
  Mean (SD) | – | 5.0 (5.66) | 9.7 (4.68) | 11.3 (4.11) | 14.0 (5.43) |
  Median (range) | – | 5.0 (1.0–9.0) | 9.0 (3.0–17.0) | 12.0 (6.0–15.0) | 12.0 (10.0–23.0) |
Other CRS-associated events | |||||
 High (> 38.3 °C) fevers, n (%) | – | 0 | 5 (71.4) | 4 (100) | 5 (100) |
  Duration (days) | |||||
   Mean (SD) | – | – | 8.4 (2.51) | 5.5 (3.32) | 9.2 (3.27) |
   Median (range) | – | – | 9.0 (6.0–12.0) | 5.0 (2.0–10.0) | 10.0 (4.0–13.0) |
 Admitted to ICU, n (%) | – | 0 | 1 (14.3) | 3 (75.0) | 5 (100) |
  Time to ICU admission (days) | |||||
   Mean (SD) | – | – | 19.0 | 28.3 (38.08) | 5.6 (4.04) |
   Median (range) | – | – | 19.0 (19.0–19.0) | 11.0 (2.0–72.0) | 3.0 (2.0–10.0) |
  Duration of ICU stay (days) | |||||
   Mean (SD) | – | – | 4.0 | 5.3 (1.15) | 12.8 (11.26) |
   Median (range) | – | – | 4.0 (4.0–4.0) | 6.0 (4.0–6.0) | 9.0 (4.0–32.0) |
  Patient dialyzed, n (%) | – | 0 | 0 | 0 | 0 |
  Pulmonary abnormalities, n (%) | – | 0 | 0 | 0 | 2 (40.0) |
Anti-cytokine therapy | |||||
 Systemic anti-cytokine therapy given, n (%) | – | 0 | 1 (14.3) | 2 (50.0) | 4 (80.0) |
  Tocilizumab | – | – | 1 (14.3) | 1 (25.0) | 4 (80.0) |
   1 dose | – | – | 1 (14.3) | 1 (25.0) | 3 (60.0) |
   2 doses | – | – | 0 | 0 | 1 (20.0) |
  Corticosteroids | – | – | 0 | 2 (50.0) | 2 (40.0) |
  Other | – | – | 0 | 0 | 0 |